Orthocell secured approval for use of Remplir across 221 facilities in the US Department of Defense and Veterans Affairs networks, including 51 military hospitals and 170 VA medical centers. This certification opens direct access to key surgeons treating traumatic nerve injuries within these integrated healthcare systems.

The device has been used in 23 surgical procedures on injured soldiers in Ukraine, demonstrating portability, ease of use and effectiveness in primary and secondary nerve repair under high-intensity conditions. These real-world cases provide critical evidence for adoption by military and VA surgeons.

Orthocell’s existing distributor network covers 17 states, supporting efficient rollout into newly approved facilities. The company has secured 32 Value Analysis Committee approvals covering 115 hospitals and has 57 additional applications in progress to expand hospital-level access.

This approval builds on April 2025 regulatory clearance and early US sales momentum, positioning Remplir for accelerated revenue growth. Orthocell is scaling manufacturing capacity and deepening engagement with healthcare providers and distribution partners to meet rising demand.